Glyn Taylor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2786078/publications.pdf

Version: 2024-02-01

		304743	2	289244
50	1,668	22		40
papers	citations	h-index		g-index
50	50	50		1369
all docs	docs citations	times ranked		citing authors
313 90				

#	Article	IF	CITATIONS
1	The stability of liposomes to nebulisation. International Journal of Pharmaceutics, 1990, 58, 57-61.	5.2	117
2	The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharmaceutical Research, 1992, 09, 764-768.	3.5	116
3	The effects of pharmaceutical excipients on drug disposition. Advanced Drug Delivery Reviews, 2007, 59, 1482-1503.	13.7	111
4	Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler Thorax, 1995, 50, 639-644.	5.6	90
5	A Gamma Scintigraphy Study to Investigate Lung Deposition and Clearance of Inhaled Amikacin-Loaded Liposomes in Healthy Male Volunteers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2009, 22, 131-138.	1.4	88
6	The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharmaceutical Research, 1989, 06, 633-636.	3.5	87
7	Standardization of Techniques for Using Planar (2D) Imaging for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, S-10-S-28.	1.4	87
8	Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered Via a Novel (Tempoâ,,¢) Inhaler. Headache, 2008, 48, 355-367.	3.9	69
9	Mode of Breathingâ€"Tidal or Slow and Deepâ€"through the I-neb Adaptive Aerosol Delivery (AAD) System Affects Lung Deposition of ^{99m} Tc-DTPA. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, S-37-S-43.	1.4	66
10	Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes. International Journal of Pharmaceutics, 1990, 58, 49-55.	5.2	64
11	The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharmaceutical Research, 1995, 12, 356-359.	3.5	59
12	Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. International Journal of Pharmaceutics, 2000, 198, 63-70.	5.2	50
13	In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. International Journal of Pharmaceutics, 1990, 65, 85-100.	5.2	49
14	Deposition, Imaging, and Clearance: What Remains to be Done?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, S-39-S-57.	1.4	44
15	Alginate–antacid combinations: raft formation and gastric retention studies. Drug Development and Industrial Pharmacy, 2010, 36, 614-623.	2.0	42
16	Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. European Journal of Pharmaceutical Sciences, 2018, 111, 450-457.	4.0	41
17	The absorption and metabolism of xenobiotics in the lung. Advanced Drug Delivery Reviews, 1990, 5, 37-61.	13.7	38
18	Targeting caveolae for vesicular drug transport. Journal of Controlled Release, 2003, 87, 139-151.	9.9	38

#	Article	IF	CITATIONS
19	Gamma Scintigraphic Evaluation of a Novel Budesonide Dry Powder Inhaler Using a Validated Radiolabeling Technique. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 15-25.	1.2	37
20	Differential Influence of Laboratory Anaesthetic Regimens upon Renal and Hepatosplanchnic Haemodynamics in the Rat. Journal of Pharmacy and Pharmacology, 2011, 42, 693-697.	2.4	36
21	Studies of cyclodextrin inclusion complexes. IV. The pulmonary absorption of salbutamol from a complex with 2-hydroxypropyl- \hat{l}^2 -cyclodextrin in rabbits. International Journal of Pharmaceutics, 1991, 77, 303-307.	5.2	32
22	Validation of Radiolabeling of Drug Formulations for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, S-6-S-9.	1.4	32
23	Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences, 2013, 102, 3382-3394.	3.3	25
24	Improved Nasal Bioavailability of FITC-Dextran (Mw4300) from Mucoadhesive Microspheres in Rabbits. Journal of Drug Targeting, 1999, 7, 355-361.	4.4	23
25	Partitioning of Oxamniquine into Brain Tissue Following Intravenous Administration to Female Wistar Rats. Drug and Chemical Toxicology, 1990, 13, 347-354.	2.3	22
26	Differential effects of anesthetic regimens on gentamicin pharmacokinetics in the rat: a comparison with chronically catheterized conscious animals. Pharmaceutical Research, 1990, 07, 41-45.	3.5	20
27	Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. Biomedical Applications, 1982, 230, 194-198.	1.7	18
28	Synthesis, characterization and release of cromoglycate from dextran conjugates. International Journal of Pharmaceutics, 1992, 83, 233-239.	5.2	17
29	Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia, 2012, 32, 150-158.	3.9	17
30	In Vitro Reporter Gene Transfection via Plasmid DNA Delivered by Metered Dose Inhaler. Journal of Pharmaceutical Sciences, 2010, 99, 3089-3099.	3.3	15
31	Aerosols for Macromolecule Delivery. American Journal of Drug Delivery, 2004, 2, 143-155.	0.6	14
32	The <i>In Vitro </i> Characterisation and Biodistribution of some Non-Ionic Surfactant Coated Liposomes in the Rabbit. Journal of Drug Targeting, 1995, 3, 39-49.	4.4	12
33	Effect of Gender and Device Mouthpiece Shape on Bolus Insulin Aerosol Delivery Using the AERxPulmonary Delivery System. Pharmaceutical Research, 2004, 21, 1776-1782.	3.5	9
34	Effect of promethazine and isosafrole on rat-hepatic microsomal mono-oxygenase activity: comparison with classic inducers phenobarbitone and \hat{l}^2 -naphthoflavone. Xenobiotica, 1985, 15, 243-249.	1.1	8
35	Anaesthetic influences on brain haemodynamics in the rat and their significance to biochemical, neuropharmacological and drug disposition studies. Biochemical Pharmacology, 1989, 38, 2745-2748.	4.4	8
36	Challenges and innovations in effective pulmonary systemic and macromolecular drug deliveryâ [*] †. Advanced Drug Delivery Reviews, 2006, 58, 993-995.	13.7	8

#	Article	IF	CITATIONS
37	Elimination of non-reactive and weakly reactive human $\hat{l}\pm 1$ -acid glycoprotein after induction of the acute phase response in rats. Journal of Pharmacy and Pharmacology, 2011, 44, 447-450.	2.4	8
38	Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022, 35, 179-185.	1.4	8
39	Route dependent pulmonary first-pass metabolism of a series of biphenylacetic acid esters in rats. European Journal of Pharmaceutical Sciences, 1998, 6, 11-18.	4.0	7
40	Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat. European Journal of Drug Metabolism and Pharmacokinetics, 1990, 15, 199-202.	1.6	6
41	Pulmonary and blood enzyme kinetics as predictors of pulmonary metabolism of esters. International Journal of Pharmaceutics, 1995, 116, 231-236.	5. 2	6
42	The influence of lipophilicity upon the nasal absorption of a series of hexapeptides. International Journal of Pharmaceutics, 1996, 135, 191-197.	5. 2	5
43	In vitro and in vivo release of estradiol from an intra-muscular microsphere formulation. International Journal of Pharmaceutics, 1997, 148, 55-61.	5.2	5
44	Pulmonary first-pass and steady-state metabolism of phenols. Pharmaceutical Research, 1996, 13, 744-748.	3. 5	4
45	Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity. International Journal of Pharmaceutics, 2000, 195, 13-16.	5. 2	4
46	Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDCâ€0214 in healthy volunteers. Clinical and Translational Science, 2022, 15, 1225-1237.	3.1	4
47	Release of cromoglycate from dextran and inulin conjugates. International Journal of Pharmaceutics, 1992, 87, 255-259.	5.2	2
48	Modified enzyme immunoassays for tobramycin using reduced sample and reagent volumes. American Journal of Health-System Pharmacy, 1987, 44, 568-571.	1.0	0
49	Cromoglycate Absorption from Rabbit Lung After Administration of A Dextran Conjugate. Journal of Pharmacy and Pharmacology, 2011, 42, 14P-14P.	2.4	0
50	Fundamental Pharmacokinetics., 2005,, 55-75.		0